Guggenheim Capital’s Altimmune ALT Stock Holding History

Guggenheim Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-52	Closed	-$12K	–	2830
2017 Q1	$12K	Hold	52	–	–	﹤0.01%	2806
2016 Q4	$50K	Buy	52 +2	+4%	+$1.79K	﹤0.01%	2803
2016 Q3	$44K	Sell	50 -1	-2%	-$784	﹤0.01%	2774
2016 Q2	$38K	Buy	51 +6	+13%	+$4.1K	﹤0.01%	2783
2016 Q1	$25K	Buy	45 +5	+13%	+$2.56K	﹤0.01%	2816
2015 Q4	$23K	Hold	40	–	–	﹤0.01%	2912
2015 Q3	$16K	Buy	40 +5	+14%	+$2.37K	﹤0.01%	2909
2015 Q2	$19K	Hold	35	–	–	﹤0.01%	2999
2015 Q1	$17K	Buy	+35	New	+$17.4K	﹤0.01%	2999
2014 Q3	–	Sell	-92	Closed	-$39K	–	2994
2014 Q2	$39K	Sell	92 -9	-9%	-$4.07K	﹤0.01%	3105
2014 Q1	$55K	Buy	101 +23	+29%	+$13.4K	﹤0.01%	3114
2013 Q4	$43K	Buy	78 +5	+7%	+$2.98K	﹤0.01%	3072
2013 Q3	$46K	Hold	73	–	–	﹤0.01%	2944
2013 Q2	$35K	Buy	+73	New	+$36.2K	﹤0.01%	2938

Other funds holding ALT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Guggenheim Capital's ALT Position: Q2 2017 in Review

Guggenheim Capital sold out of Altimmune (ALT) in Q2 2017, closing a stake of 52 shares — an estimated $12K sold.

Guggenheim Capital first reported a position in ALT in Q2 2013 and held it in 14 quarters. The position peaked at $55K in Q1 2014. 41 funds tracked by Wall St. Rank hold ALT as of Q2 2017.

Guggenheim Capital reported no remaining Altimmune position as of Q2 2017 after selling out during the quarter.
Guggenheim Capital sold 52 Altimmune shares in Q2 2017, an estimated $12K.
Guggenheim Capital first reported a position in Altimmune in Q2 2013 and held it in 14 quarters.
Guggenheim Capital's Altimmune position peaked at $55K in Q1 2014.
41 funds tracked by Wall St. Rank held Altimmune as of Q2 2017.

Based on Guggenheim Capital's 13F filing for Q2 2017, filed 14 Aug 2017.